Deal Certainty Mechanisms: RTFs, Ticking Fees, and Outside Dates

Introduction

The multi-layered regulatory approval process in healthcare creates deal certainty challenges that do not exist in most other M&A sectors. When a deal takes 12-18 months to close and faces FTC scrutiny at higher-than-average rates, both buyer and seller need contractual protections that allocate the risk of regulatory failure and compensate for the cost of extended waiting periods. Healthcare bankers must understand these mechanisms because they directly affect deal economics, negotiation dynamics, and the seller's ultimate realization.

Reverse Termination Fee (RTF)

A payment the buyer makes to the seller if the deal fails to close due to the buyer's inability to obtain required regulatory approvals (typically antitrust clearance). Unlike a standard termination fee (paid by the seller if it walks away from the deal), an RTF compensates the seller for the opportunity cost and damage of a failed transaction. In healthcare, RTFs appear in approximately 58% of transactions and average 4.76% of deal value. A $10 billion healthcare deal with a standard RTF would include a $476 million payment from buyer to seller if the FTC blocks the transaction.

RTFs serve two functions. First, they compensate the seller for the real costs of a failed deal: management distraction, employee attrition during the prolonged uncertainty period, competitive damage from the public announcement, and the difficulty of running a second sale process after a high-profile failure. Second, they signal the buyer's confidence in obtaining regulatory clearance. A buyer willing to commit a $500 million RTF is signaling that it believes the regulatory risk is manageable.

RTF Trigger Conditions

The specific conditions that trigger RTF payment are critically important. The standard trigger is the buyer's failure to obtain antitrust clearance by the outside date. However, the details matter: Is the RTF payable if the buyer decides not to pursue regulatory clearance (voluntary walk-away), or only if regulatory approval is actively denied? Does the RTF cover state regulatory failures in addition to federal FTC challenges? Is the RTF payable if the buyer is required to make divestitures it considers unacceptable? These conditions are heavily negotiated and should be analyzed carefully by the sell-side banker.

Ticking Fee

A contractual provision that increases the purchase price (or pays a separate fee to the seller) for each day, week, or month that closing is delayed beyond a specified trigger date. Ticking fees compensate the seller for the time value of money and opportunity cost of waiting for regulatory clearance. Typical ticking fee structures increase the purchase price by 3-5% on an annualized basis (e.g., $0.01 per share per day, or a lump-sum payment per month of delay). The trigger date is usually set 3-6 months after signing, on the assumption that the first few months of regulatory review are expected and should not generate additional compensation.

Ticking fees are particularly important in healthcare because the regulatory timeline is both long and unpredictable. A deal that signs in January with an expected closing in June might not close until December if the FTC issues a Second Request. Without a ticking fee, the seller absorbs the full cost of this 6-month delay: management distraction, employee retention challenges, competitive uncertainty, and the time value of the deferred purchase price.

The outside date (also called the "drop-dead date" or "long-stop date") is the date after which either party can terminate the transaction if closing has not occurred. In healthcare, outside dates are typically set at 12-18 months from signing, with provisions for one or two automatic extensions of 3-6 months if regulatory review is still pending.

The length of the outside date reflects a trade-off. Sellers want shorter outside dates to limit the uncertainty period and preserve the option to pursue alternative transactions if the deal stalls. Buyers want longer outside dates to provide sufficient time for regulatory clearance, including potential litigation with the FTC. Healthcare's multi-layered regulatory process generally pushes outside dates longer than in other sectors.

Hell-or-High-Water Provision

A contractual commitment by the buyer to take any and all steps necessary to obtain regulatory clearance, including divesting overlapping businesses, accepting behavioral remedies, or agreeing to consent decrees, regardless of the cost to the buyer's broader business. Hell-or-high-water provisions represent the strongest possible commitment to regulatory clearance and are typically demanded by sellers in transactions with significant antitrust risk. The provision effectively shifts all regulatory risk to the buyer: if the FTC requires divestitures, the buyer must make them, even if the required divestitures reduce the strategic value of the acquisition.

Hell-or-high-water provisions are relatively rare in healthcare because buyers are understandably reluctant to make open-ended commitments that could require divesting significant business units. More common are "reasonable best efforts" obligations with negotiated limitations on required divestitures (for example, the buyer must agree to divestitures representing up to 10% of the target's revenue, but not more).

The next article covers MAE clauses and healthcare-specific carveouts, exploring how the Material Adverse Effect definition is customized for healthcare transactions.